BA401_EliLilly and Company: Drug Development Strategy(A)

936 views
853 views

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
936
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
20
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

BA401_EliLilly and Company: Drug Development Strategy(A)

  1. 1. Eli Lilly and Company<br />:Drug Development Strategy (A)<br />
  2. 2. Introduction to <br />the Pharmaceutical Industry<br />In the mid 1990s<br />
  3. 3. By the mid 1990s, annual worldwide pharmaceutical <br />sales were around $250 billion, with roughly 80 percent <br />originating in the industrialized G7 nations. <br />Top Blockbuster drugs targeted diseases of particular <br />concern to industrialized nations.<br />
  4. 4. U.S. Pharmaceutical Market <br />by Therapeutic Category (1994)<br />
  5. 5.
  6. 6. Summary of Drug Development <br />in the USA<br />
  7. 7.
  8. 8. Under current law, a patent’s term expired <br />20 years from the time the patent application <br />was field (prior to 1995, patent protection <br />extended 17 years after the patent was issued.)<br /> Sales of only a few products could provide <br />exceptional returns. In the mid 1990s, <br />14 products had annual sale over $1 billion, <br />enabling profit margins of 15-20 percent.<br />
  9. 9. Top 20 Prescription Drugs by <br />Worldwide Sales (1994)<br />(dollar in millions)<br />
  10. 10.
  11. 11. Top 20 Firms Active in the <br />Pharmaceutical Industry (1994)<br />(dollars in millions)<br />
  12. 12.
  13. 13. Eli Lilly and Company<br />
  14. 14. Eli Lilly and Company was <br />found In Indianapolis, Indiana <br />in 1876 by Colonel Eli Lilly.<br /> In the mid 1990s, Lilly, <br />operating in 150 countries, <br />was one of the world’s largest pharmaceutical <br />company, with over <br />25,000 employees and <br />1994 sales of $5.7 billion.<br />
  15. 15. Eli Lilly and Company<br />- Organization Chart <br />
  16. 16. Chairman and CEO<br />R. L. Tobias<br />A. M. Watanabe, MD<br />Executive VP Science &<br />Technology<br />VP, Human<br />Resources<br />Executive VP,<br />Finance & CFO<br />VP & General<br />Counsel<br />President<br />& COO<br />VP, <br />Cardiovascular<br />Eisenstein, MD<br />VP Technology Core &<br />Infectious Disease<br />VP, <br />Regulatory Affairs<br />CNS Business<br />Unit<br />VP, <br />Endocrinology<br />VP, <br />Development<br />M. Haslanger, PhD<br />Executive Director,<br />Research Technology<br />And Proteins,<br />President, Sphinx<br />Pharmadeuticals<br />VP, <br />Cancer<br />VP, Medical<br />(Phases II & III)<br />VP, Central<br />Nervous System<br />Bianca Sharma,<br />Project Manager<br />S. Kaldor, PhD, Head of<br />Combinatorial Chemistry<br />J. Schaus, PhD, Senior<br />Research Scientist<br />
  17. 17. Eli Lilly and Company<br /><ul><li>1994 Financial Highlights</li></ul>(dollars in million)<br />
  18. 18.
  19. 19. Eli Lilly and Company<br /><ul><li>Major Product Sales</li></ul>(dollars in million)<br />
  20. 20.
  21. 21. Innovation in the new Drug<br />Development Process<br />
  22. 22.
  23. 23. Combinatorial Chemistry<br />At Lilly<br />
  24. 24. Combinatorial chemistry is an emerging <br />technology for generating a large collection <br />or “library” of related chemical compounds <br />rapidly, instead of having to make one <br />compound at a time. This allows for creating <br />variations around the backbone of a basic <br />molecular structure.<br />
  25. 25. Combinatorial Chemistry <br />(the “Split-and-Mix” Method) <br />
  26. 26. Central Nervous System<br />(CNS) Diseases<br />
  27. 27. CNS Diseases accounted for roughly <br />10 percent of all lifetime years lost to disease.<br />E.g. clinical depression, severe insomnia<br />(sleeplessness), and migraine<br /> Each of which affected over 10 percent <br />of the population – could take a severe toll on <br />society. For instance, depression might <br />predispose people to suicide<br />
  28. 28. Lilly’s Migraine Project<br />
  29. 29. “Migraine”<br /><ul><li>was characterized by unilateral pulsating </li></ul> headaches often severe enough to restrict <br /> physical and mental activity<br /><ul><li> afflicted 12 percent of population, </li></ul> with a 3:1 preponderance in women <br />
  30. 30. Imitrex,<br /><ul><li>launched in 1992
  31. 31. was a mildly effective drug that act by </li></ul> constricting blood vessels<br /><ul><li>had an adverse effect on the heart’s vessels</li></ul> Many scientists felt that the makers of <br />Imitrex had followed the wrong path by <br />trying to find a compound that constricted <br />blood vessels(known as “vasoconstriction”).<br />
  32. 32. By March 1994, out of over 1,000 <br />previously synthesized serotonin-like <br />compounds one particularly good “lead” <br />had been found. In addition, Lilly’s experiments <br />in which lab animals were administered these <br />lead compounds further promise of the “1f” <br />serotonin receptors as treatment targets for <br />migraine without the need for inducing <br />vasoconstriction.<br />
  33. 33. Timeline<br />
  34. 34.
  35. 35.
  36. 36.
  37. 37. Difficult choices:<br />The Project Team Advisory <br />Committee(PTAC) Meeting<br />
  38. 38. The three key business <br />issues for PTAC Presentation<br />
  39. 39.
  40. 40. Member of the group<br />วริษฐา ภิรมย์รัตน์ 4902680521<br />ณัฐกานต์ มีสัตย์ 4902682055<br />อัจฉรา บัญชากร 5002686094<br />หฤษฎ์ พรรณพานิช 5002686185  <br />

×